
Director: @HCPLiveNews, @ContempPeds, @ContempOBGYN, & @UrologyTimes. Producer: #DiabetesDialogue, #DontMissABeat, #KidneyCompass. Opinions are my own. #Ramily
New Jersey
Joined May 2011
- Tweets8.5K
- Following635
- Followers714
- Likes6.4K
Patrick Campbell retweeted
🚨 BREAKING: The @FDA has approved gefurulimab-gaks (Klygefa; @AlexionPharmaUS ) for adults with anti-AChR antibody-positive generalized myasthenia gravis (#gMG)
💉 The once-weekly, self-administered subcutaneous C5 inhibitor was approved based on phase 3 PREVAIL findings
🧠 Read about the approval here: neurologylive.com/view/fda-a…
#Neurology #FDA
Patrick Campbell retweeted
The HCPLive team is in Chicago for #AHA26!
Be sure to follow along for the latest in cardiology:
hcplive.com
#cardiology
Patrick Campbell retweeted
A common theme on the podcast has been imposter syndrome and @robmentz gives a fantastic perspective on that. Very relevant for trainees and early-mid career faculty.
Lesson: it’s ok to feel vulnerable. You’re not alone.
Patrick Campbell retweeted
Day 1🗓️ of #GOLD2026 starts today in Philadelphia!
HCPLive is on-site, covering topics like mucus plugging, exacerbation definitions, and more ahead of the 2027 GOLD Report.
Follow along: hcplive.com/view/conference-…
Patrick Campbell retweeted
In this episode of #ABCsInDermatology, hosts highlight how the standard of care for atopic dermatitis is undergoing a transformative shift beyond managing symptoms to actually achieving optimal treatment targets.
hubs.li/Q04CSgHr0
Patrick Campbell retweeted
⏱️ #WorldStrokeDay: @snellingmd, of @BaptistHealthSF, says delays before the 911 call remain a major gap in stroke care.
He discusses atypical symptoms, BE FAST, and reaching underserved populations.
🚨 hubs.li/Q04CP8Vk0
#Stroke #Neurology
Big news from day 1 of #KidneyWeek2026.
Data from phase 2 and phase 3 trials of retatrutide, sibeprenlimab, telitacicept, and iptacopan headline the meeting's first day.
hcplive.com/conference/asn
#KidneyWk #NephTwitter #Nephrology
Patrick Campbell retweeted
📍 We’re on the ground for #MSToronto2026 ‼️ 🇨🇦
✍️ Coverage kicks off tomorrow, with key updates, expert insights, and the latest developments in #MS
🧠 Follow along with NeurologyLive as we bring you the stories and perspectives shaping the MS treatment landscape!
🔗 Stay tuned to our social channels and hubs.li/Q04BQHzC0 for the latest updates! 👀
#MSToronto #Clinical #MSCare
Patrick Campbell retweeted
Halfway through #CHEST2026! Check out our coverage so far on HCPLive:
hcplive.com/conference/chest
Patrick Campbell retweeted
From medication habits that may be fueling asthma exacerbations to what sputum color can tell you in bronchiectasis, here are the day 1 headlines from #CHEST2026 @accpchest worth knowing. #asthma #COPD #bronchiectasis #ildahumic #pulmonology
Read here: hcplive.com/view/chest-2026-… – at Phoenix, AZ
Patrick Campbell retweeted
🇨🇦 🧠 Bonjour from Montreal, Canada! We are here for Day 1 of the 2026 Child Neurology Society Annual Meeting!
Be on the lookout for our coverage of #CNSAM 2026, featuring expert interviews and the latest data in child neurology! 🔎 📊 @ChildNeuroSoc
Patrick Campbell retweeted
Heading to Phoenix for CHEST 2026? Our preview covers 10 late-breaking abstracts in #COPD, #asthma, #pulmonaryhypertension, & more, all presented Oct. 20. @accpchest #CHEST2026 hcplive.com/view/chest-2026-…
Patrick Campbell retweeted
All the latest data on neuromuscular disorders, electrodiagnostic medicine, and more. Here, at the 2026 #AANEM Annual Meeting in Orlando, FL ☀️🌴
@AANEMorg
Our coverage rolls on: neurologylive.com/conference…
Patrick Campbell retweeted
🧠 @FDA accepts NDA under priority review for @genentech's fenebrutinib, an oral BTK inhibitor, in both relapsing and primary progressive MS, backed by 3 phase 3 trials vs teriflunomide and ocrelizumab.
hubs.li/Q04yKx790
#MultipleSclerosis #Neurology
Patrick Campbell retweeted
For those attending #AANEM2026, here's a look at some of the top trending stories we've covered 👇
🏥 Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis - neurologylive.com/view/gefur…
📈 Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis - neurologylive.com/view/inebi…
💉 Zilucoplan Autoinjector Matches Bioequivalence of Pre-Filled Syringe in MG - neurologylive.com/view/ziluc…
📊 New Phase 3 Trials to Test Empasiprubart Against Placebo, IVIG in CIDP - neurologylive.com/view/empas…
For all AANEM coverage, click here: neurologylive.com/conference…
Patrick Campbell retweeted
WATCH: Rahul Mehan, MD, (@RahulMehan1) discusses the evolving landscape of minimally invasive BPH therapy. urologytimes.com/view/the-ev…
Patrick Campbell retweeted
Vienna, here we come. 🇦🇹
Tomorrow, HCPLive's coverage of #EADV2026 kicks off. Starting Sept 30, expect expert interviews, late-breaking data, and more.
Follow along for dermatology updates you won't want to miss: hcplive.com/conference/europ…
Patrick Campbell retweeted
Advocacy isn't separate from patient care. It's part of it.
AAD President Murad Alam, MD, joins Elizabeth Kiracofe, MD, on the Skin of Color Savvy podcast 🎙️ to explain why.
🎧More: hcplive.com/view/reimburseme…
Patrick Campbell retweeted
AUA South Central Section Meeting Recap teapawt.net/i/broadcasts/1kKzDPdgd…
Patrick Campbell retweeted
A major step forward in type 1 diabetes care: Tzield is now approved for children as young as 1.
#Type1Diabetes #FDA #PediatricHealth #Diabetes #EarlyIntervention #T1D
Watch our interview with diabetes expert Rachael Sood, NP-C, to learn more about what this means for families:
hubs.li/Q04d4Mc30



















